Votrient is a medication that contains the active ingredient pazopanib hydrochloride. It belongs to a class of drugs known as tyrosine kinase inhibitors and is primarily used in the treatment of certain types of cancer. Below is a general description:

Pazopanib (Votrient):

Indications:

• Renal Cell Carcinoma (Kidney Cancer): Pazopanib is indicated for the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer, in adults.
• Soft Tissue Sarcoma: Pazopanib is also approved for the treatment of advanced soft tissue sarcoma in patients who have received prior chemotherapy.

Mechanism of Action:

• Pazopanib inhibits the activity of multiple tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and stem cell factor receptor (c-KIT). By blocking these receptors, pazopanib interferes with the growth and spread of cancer cells, as well as the development of new blood vessels that tumors need to grow.

Administration:

• Pazopanib is typically taken orally in the form of tablets. The dosage and schedule may vary based on the specific type of cancer being treated and the overall treatment plan.

Dosage:

• The standard dosage of pazopanib for renal cell carcinoma and soft tissue sarcoma is typically 800 mg once daily. However, the dosage may be adjusted by a healthcare provider based on individual patient factors, such as tolerance to side effects.

Duration of Treatment:

• Treatment with pazopanib may continue as long as the patient continues to benefit from the medication and does not experience unacceptable side effects.

Monitoring:

• Patients receiving pazopanib may undergo regular medical evaluations, including blood tests and imaging studies, to monitor treatment response and manage potential side effects.

Side Effects:

• Common side effects of pazopanib may include diarrhea, hypertension (high blood pressure), fatigue, nausea, vomiting, and changes in liver function tests. Serious side effects, although less common, may include liver toxicity, heart problems, and bleeding.

Contraindications and Precautions:

• Pazopanib may be contraindicated in individuals with a history of severe hypersensitivity reactions to the drug or its components. It should be used with caution in patients with pre-existing liver or kidney dysfunction.

Patient Counseling:

• Patients prescribed pazopanib should be educated about potential side effects, the importance of adhering to the treatment plan, and the need for regular medical monitoring.

Pregnancy and Breastfeeding:

• Pazopanib may have potential risks during pregnancy, and its use should be carefully considered in consultation with healthcare providers. Breastfeeding is not recommended during pazopanib therapy.

It’s important to note that specific details about the use of Votrient (pazopanib) should be discussed with a healthcare professional or obtained from the prescribing information provided by the pharmaceutical manufacturer. The medication should be used under the guidance and supervision of a qualified healthcare provider based on the individual’s medical history and specific health needs.